These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9685166)

  • 1. Malignant disorders of megakaryocytes.
    Cripe LD; Hromas R
    Semin Hematol; 1998 Jul; 35(3):200-9. PubMed ID: 9685166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Megakaryoblastic termination of myeloproliferative disorders.
    Amin MB; Maeda K; Carey JL; Babu RV; Raman BK
    Henry Ford Hosp Med J; 1992; 40(1-2):122-6. PubMed ID: 1428963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myelodysplastic syndromes and myeloproliferative disorders.
    Williams JL
    Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Unusual case of chronic myeloproliferative syndrome].
    Tosato F; Fossaluzza V
    Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myeloproliferative disorders.
    Gilbert HS; Dameshek W
    Dis Mon; 1970 Oct; ():1-52. PubMed ID: 4921953
    [No Abstract]   [Full Text] [Related]  

  • 11. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute myelofibrosis and acute megakaryoblastic/megakaryocytic leukemia. A study on clinicopathologic correlations in a patient and reports of the literature].
    Hirano K; Takenaka T; Nakamine H; Oshiro I; Maeda J; Kishi T; Murakami S; Yokoya Y; Nishioka S; Yataka I
    Rinsho Ketsueki; 1984 Aug; 25(8):1290-8. PubMed ID: 6542604
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micromegakaryocytic transformation of myelofibrosis with myeloid metaplasia.
    Rosangela I; Pecci A; Formisano R
    Haematologica; 2000 Jan; 85(1):98-9. PubMed ID: 10629600
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic megakaryocytic myelosis; agnogenic myeloid metaplasia.
    RICKER W
    Northwest Med; 1948 Oct; 47(10):737-40. PubMed ID: 18888892
    [No Abstract]   [Full Text] [Related]  

  • 18. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.